Feeding EPA and DHA Improve Clinical Symptoms Associated with COVID-19 Infection
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:1 publications
Grant number: 174885
Grant search
Key facts
Disease
COVID-19Start & end year
20212022Known Financial Commitments (USD)
$271,957.5Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
Vera C MazurakResearch Location
CanadaLead Research Institution
University of AlbertaResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Prognostic factors for disease severity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The purpose of this study is to find out if the amount of a certain type of fat in the body, called n-3 fatty acids, is related to the severity of COVID-19 symptoms. Currently, it is known that higher amounts of n-3 fatty acids improve outcomes in some conditions. This study will test whether increasing n-3 fatty acids through a medical food improves the clinical outcomes and severity of COVID-19 infection. Patients admitted to the ICU will be randomized to receive a medical food containing n-3 fatty acids or one without. Blood samples will drawn at specific points during the care of patients who have COVID-19. These blood samples will be examined for fatty acids and level of inflammation. Clinical data regarding symptoms and progression or resolution of disease will be collected from patients medical records. Groups will be compared on level of n-3 fatty acids and the association with inflammation, symptoms and disease progression. We hope this study will lead to simple treatment options involving nutritional strategies designed to significantly raise the individual patient's plasma n-3 fatty acid levels.
Publicationslinked via Europe PMC
Last Updated:an hour ago
View all publications at Europe PMC